A supplemented high-fat low-carbohydrate diet for the treatment of glioblastoma

Clinical Cancer Research

Volumn 22, Issue 10, 2016, Pages 2482-2495

  Martuscello, Regina T ^a   Vedam Mai, Vinata ^a,b   McCarthy, David J ^a   Schmoll, Michael E ^a   Jundi, Musa A ^a   Louviere, Christopher D ^a   Griffith, Benjamin G ^a   Skinner, Colby L ^a   Suslov, Oleg ^a   Deleyrolle, Loic P ^a   Reynolds, Brent A ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; KETONE; MAMMALIAN TARGET OF RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER STEM CELL; CELL PROLIFERATION; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KETOGENIC DIET; LIPID DIET; LOW CARBOHYDRATE DIET; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL EXPANSION; SUPPLEMENTED HIGH FAT LOW CARBOHYDRATE DIET; SURVIVAL; ANIMAL; BRAIN TUMOR; DIET THERAPY; DISEASE MODEL; DRUG SCREENING; METABOLISM; NONOBESE DIABETIC MOUSE; PHYSIOLOGY; PROCEDURES; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DIET, CARBOHYDRATE-RESTRICTED; DIET, HIGH-FAT; DIET, KETOGENIC; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; GLUCOSE; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84968735483     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0916     Document Type: Article

References (57)

1. Fuentes-Raspall R, Puig-Vives M, Guerra-Prio S, Perez-Bueno F, Marcos-Gragera R. Population-based survival analyses of central nervous system tumors from 1994 to 2008. An up-dated study in the temozolomide-era. Cancer Epidemiol 2014;38:244-7.
2. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012;21:297-308.
3. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
4. Seyfried TN, Flores R, Poff AM, D'Agostino DP, Mukherjee P. Metabolic therapy: a new paradigm for managing malignant brain cancer. Cancer Lett 2014;356:289-300.
5. Woolf EC, Scheck AC. The ketogenic diet for the treatment of malignant glioma. J Lipid Res 2015;56:5-10.
6. VanItallie MDTB, Thomas H, Nufert BA. Ketones: metabolism's ugly duckling. Nutr Rev 2003;61:327-41.
7. Veech R. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids 2004;70:309-28.
8. Patel MS, Russell JJ, Gershman H. Ketone-body metabolism in glioma and neuroblastoma cells. Proc Natl Acad Sci USA 1981;78:7214-8.
9. Poff AM, Ari1 CP, Arnold TN, Seyfried D'Agostino DP. Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. Int J Cancer 2014;135:1711-20.
10. Macleod KF. Mitochondrial dysfunction in cancer. Fronteirs Oncol 2013; 3:1-28.
11. Stafford P, Abdelwahab MG, Kim DY, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab 2010;7:1-11.
12. Scheck AC, Abdelwahab MG, Fenton KE, Stafford P. The ketogenic diet for the treatment of glioma: insights from genetic profiling. Epilepsy Res 2011;100:327-37.
13. Poff AM, Ari C, Seyfried TN, D'Agostino DP. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. Plos ONE 2013;8:e65522.
14. Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, Seyfried TN. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab 2007;4:1-15.
15. Seyfried BTN, Kiebish M, Marsh J, Mukherjee P. Targeting energy metabolism in brain cancer through calorie restriction and the ketogenic diet. J Cancer Res Ther 2009;5:S7-15.
16. Nebeling L, Floro Miraldi, Shurin S, Lerner E. Effects of a ketogenic diet on tumor metabolism and nutitional status in pediatric oncology patients: two case reports. J Am College Nutr 1995;14:202-8.
17. Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukhergee P, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. Nutr Metab 2010;7:33-40
18. Rieger J, Bahr O, Maurer GD, Hattingen E, Franz K, Brucker D, et al. ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol 2014; 44:1843-52.
19. Schmidt M, Pfetzer N, Schwab M, Strauss I, Kämmerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutr Metab 2011;8:54-67.
20. Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol 2014;117: 125-31
21. Simone BA, Champ CE, Rosenberg AL, Berger AC, Monti DA, Dicker AP, et al. Selectively starving cancer cells through dietary manipulation: methods and clinical implications. Future Oncol 2013;9:959-76.
22. Lv M, Zhu X, Wang H, Wang F, Guan W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and metaanalysis. PloS ONE 2014;9:1-17.
23. Azari H, Millette S, Ansari S, Rahman M, Deleyrolle LP, Reynolds BA. Isolation and expansion of human glioblastoma multiforme tumor cells using the neurosphere assay. J Visualized Exp 2011;56:1.
24. Deleyrolle LP, Ericksson G, Morrison BJ, Lopez JA, Burrage K, Burrage P, et al. Determination of somatic and cancer stem cell self-renewing symmetric division rate using sphere assays. PLoS ONE 2011;6:e15844.
25. Deleyrolle LP, Harding A, Cato K, Siebzehnrubl FA, Rahman M, Azari H, et al. Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain 2011;134:1331-43.
26. Siebzehnrubl FA, Silver DJ, Tugertimur B, Deleyrolle LP, Siebzehnrubl D, Sarkisian MR, et al. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med 2013;5:1196-212.
27. Meidenbauer JJ, Purna Mukherjee, Seyfried TN. The glucose ketone index calculator: a simple tool to monitor therapeutic efficacy for metabolic management of brain cancer. Nutr Metab 2015;12:1-7.
28. Dirks AJ, Leeuwenburgh C. Caloric restriction in humans: Potential pitfalls and health concerns. Mech Ageing Dev 2005;127:1-7.
29. Wibisono C, Rowe N, Beavis E, Kepreotes H, Mackie FE, Lawson JA, et al. Ten-year single-center experience of the ketogenic diet: factors influencing efficacy, tolerability, and compliance. J Pediatr 2015;166:1030-6
30. Garbow JR, Doherty JM, Schugar RC, Travers S, Weber ML, Wentz AE, et al. Hepatic steatosis, inflammation, and ER stress in mice maintained long term on a very low-carbohydrate ketogenic diet. Am J Physiol Gastrointest Liver Physiol 2011;300:G956-67.
31. Kwiterovich PJr, Vining E, Pysik P, Skolasky RJr, Freeman J. Effects of a highfat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. JAMA 2003;290:912-20.
32. Schugar RC, Xiaojing Huang, Moll Ashley R, Brunt Elizabeth M, Crawford PA. Role of choline deficiency in the Fatty liver phenotype of mice fed a low protein, very low carbohydrate ketogenic diet. PLoS ONE 2013;8:e74806-e74806.
33. Oleksyszyn J. The complete control of glucose level utilizing the composition of ketogenic diet with the gluconeogenesis inhibitor, the antidiabetic drug metformin, as a potential anti-cancer therapy. Med Hypotheses 2011;77:171-3.
34. Luchman HA, Stechishin ODM, Nguyen SA, Lina XQ, Cairncross G, Weiss S. Dual mTORC1/2 Blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Clin Cancer Res 2014;20:5756-67.
35. Alayev A, Holz MK. mTOR signaling for biological control and cancer. J Cell Physiol 2013;228:1658-64.
36. Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M, et al. eIF4E/ 4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res 2012;72:6468-76.
37. Lee J, Kotliarova S, Kotilarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serumcultured cell lines. Cancer Cell 2006;9:391-403.
38. Galli R, Binda E, Orfanello U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011-21.
39. Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, et al. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells 2009;27:980-7.
40. McGirt MJ, Chaichana KL, Gathinji M, Atenello F, Than K, Ruiz AJ, et al. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery 2008;63:286-291.
41. Silvera SAN, Meera Jain2, Howe Geoffrey R., Miller Anthony B., Rohan TE. Dietary carbohydrates and breast cancer risk: A prospective study of the roles of overall glycemic index and glycemic load. Int J Cancer 2005;114: 653-8.
42. Ho VW, Leung K, Hsu A, Luk B, Lai J, Shen SY, et al. A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Res 2011;71:4484-93.
43. Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P, et al. Effect of 2-Deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res 2006;26:3561-6.
44. Maurer GD, Brucker DP, Bahr O, Harter PN, Hattingen E, Walenta S, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer 2011;11:315.
45. Chang HT, Olson LK, Schwartz KA. Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: Implication for ketogenic diet therapy. Nutr Metab 2013;10:47-53.
46. Skinner R, Trujillo A, Ma X, Beierle EA. Ketone bodies inhibit the viability of human neuroblastoma cells. J Pediatr Surg 2009;44:212-6.
47. Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, et al. Suppression of oxidative stress by b -hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013;339:211-4.
48. Bose P, Yun Dai, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights. Pharmacol Ther 2014;143:323-36.
49. Wu G Y, Thompson JR. The effect of ketone bodies on alanine and glutamine metabolism in isolated skeletal muscle from the fasted chick. Biochem J 1988;255:139-44.
50. Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab 2014;25:42-52.
51. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavildes S, Pestell RG, Chiavarina B, et al. Ketones and lactate fuel tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010;9:3506-14.
52. Cairns RA, Isaac S. Harris, Mak TW. Regulation of cancer cell metabolism. Nat Rev 2011;11:85-95.
53. Otto C, Kaemmerer U, Illert B, Muehling B, Pfetzer N, Wittig R, et al. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer 2008;8:122-34.
54. Hao G-W, Chen Y-S, He D-M, Wang H-Y, Wu G-H, Zhang B. Growth of human colon cancer cells in nude mice is delayed by ketogenic diet with or without omega-3 fatty acids and medium-chain triglycerides. Asian Pac J Cancer Prev 2015;16:2061-8.
55. Tisdale MJ, Brennan RA. A comparison of long-chain triglycerides and medium-chain triglycerides on weight loss and tumour size in a cachexia model. Br J Cancer 1988;58:580-3.
56. Mcdaniel SS, Rensing NR, Thio LL, Yamada KA, Wong M. The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia 2011;52:e7-11.
57. Danial NN, Hartman AL, Stafstrom CE, Thio LL. How does the ketogenic diet work?: Four potential mechanisms. J Child Neurol 2013;0: 1-7.